Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proof-of-concept trial of itepekimab in chronic rhinosinusitis without nasal polyps
2024-515576-12-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis (CRS) comparing Itepekimab with Placebo (2 arms). Primary endpoint: Change from baseline in sinus percent opacification volume. Started Mar 2025; status: completed.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on 2024-515576-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515576-12-00.